Is Ozempic Good for Weight Loss?

In the pursuit of effective weight loss solutions, pharmaceutical advancements have introduced various medications aimed at addressing obesity and related health concerns. One such medication gaining attention is Ozempic (semaglutide), primarily known for its use in managing type 2 diabetes. However, recent studies and clinical trials have also highlighted its potential in aiding weight loss beyond its original therapeutic purpose.

Understanding Ozempic

Ozempic belongs to a class of drugs called GLP-1 receptor agonists, designed to mimic the effects of glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar levels. Originally used for treating type 2 diabetes, Ozempic works by stimulating insulin production, reducing glucose release from the liver, and slowing down digestion to help control blood sugar levels in diabetic patients.

The Link to Weight Loss

While Ozempic's primary indication is diabetes management, its impact on weight loss has sparked significant interest. Clinical trials, such as the STEP trials (Semaglutide Treatment Effect in People with Obesity), have demonstrated promising results. Participants in these trials experienced substantial weight loss over a period of 68 to 68 weeks, with some achieving an average weight loss of around 15-17% of their initial body weight. Such outcomes have positioned Ozempic as a potential tool for combating obesity, particularly in individuals struggling with significant weight issues.

Mechanisms of Weight Loss

The weight loss effects of Ozempic are attributed to several mechanisms:

  • Appetite Suppression: Ozempic helps reduce appetite by acting on the hypothalamus, the part of the brain responsible for hunger and satiety signals. This leads to decreased food intake, which contributes to weight loss over time.
  • Slowed Gastric Emptying: By delaying the emptying of food from the stomach, Ozempic prolongs feelings of fullness (satiety) after meals. This can help individuals consume fewer calories and better manage their weight.
  • Increased Energy Expenditure: Some studies suggest that Ozempic may also increase energy expenditure, though the exact mechanisms behind this effect are still being researched.
  • Clinical Evidence and Trials: The STEP trials have been pivotal in establishing Ozempic's efficacy in weight management. These trials involved thousands of participants and showed consistent and significant weight loss results across different patient demographics. Notably, individuals with obesity and those without diabetes both experienced substantial reductions in body weight when treated with Ozempic.

Considerations and Safety

Like any medication, Ozempic is not without potential side effects. Common side effects include nausea, vomiting, diarrhea, and constipation, particularly when starting the medication. These symptoms often improve over time as the body adjusts to the medication. Additionally, there are considerations for specific patient populations, such as pregnant or breastfeeding women, where the use of Ozempic may not be recommended due to limited safety data.

Ozempic represents a significant advancement in the treatment of both type 2 diabetes and obesity. Its dual benefits of improving glycemic control and promoting weight loss make it a valuable option for healthcare providers and patients alike. However, as with any medical treatment, individual responses can vary, and it should be used under the guidance of a healthcare professional.


  • Wilding, J.P.H. et al. (2021) ‘Once-weekly semaglutide in adults with overweight or obesity’, New England Journal of Medicine, 384(11), pp. 989–1002. doi:10.1056/nejmoa2032183.
  • Pi-Sunyer, X. et al. (2015) ‘A randomized, controlled trial of 3.0 mg of liraglutide in weight management’, New England Journal of Medicine, 373(1), pp. 11–22. doi:10.1056/nejmoa1411892.
  • Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017 Sep;19(9):1242-1251. doi: 10.1111/dom.12932. Epub 2017 May 5. PMID: 28266779; PMCID: PMC5573908.

To provide you with the best experience with Be Fit Food, we have ensured a range of documents are available to you including: Incident Management Policy, Complaints Management Policy and Complaints Management Form. If you need assistance with any of these documents, please contact our Customer Service team on 1300 263 257.